TG Therapeutics Inc

1TGTX

Company Profile

  • Business description

    TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

  • Contact

    3020 Carrington Mill Boulevard
    Suite 475
    MorrisvilleNC27560
    USA

    T: +1 212 554-4484

    E: [email protected]

    https://www.tgtherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    352

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,571.4040.30-0.47%
CAC 407,845.9364.56-0.82%
DAX 4023,980.39142.01-0.59%
Dow JONES (US)41,811.0449.40-0.12%
FTSE 1008,719.9066.56-0.76%
HKSE23,544.31283.47-1.19%
NASDAQ18,962.1689.520.47%
Nikkei 22536,985.87313.11-0.84%
NZX 50 Index12,662.2540.85-0.32%
S&P 5005,842.212.40-0.04%
S&P/ASX 2008,348.7038.10-0.45%
SSE Composite Index3,380.197.39-0.22%

Market Movers